RxDoctor Payments Data

Kyle Otteson, OD

Optometrist · Bismarck, NDNPI 1679907307

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $694 of the $934 with a category attached, or 74.3%. 8 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 34.9% of the total. Reporting peaked in 2024 at $263 and has fallen 74.8% since, to $66 in 2025.

$934in general payments, 2019–2025

Across 21 payments — averaging $44.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$326
  • The Walman Optical Company$240
  • Alcon$177
  • Glaukos Corporation$83
  • Coopervision Inc.$58
  • Dompe US, Inc.$20
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$69474%
  • Gifts$24026%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bausch & Lomb Americas Inc.6$326
The Walman Optical Company1$240
Alcon6$177
Glaukos Corporation3$83
Coopervision Inc.2$58
Dompe US, Inc.1$20
Aerie Pharmaceuticals, Inc.1$15
AbbVie1$14

How this compares

$934 in reported general payments places this provider in the 75th percentile of 179 optometrist providers in North Dakota.

See all optometrist providers in North Dakota

Medicare billing

Part B allowed, 2024
$53,916
Medicare patients
445
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost38$457
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha34$448

Paid to pharmacies, not to this prescriber.

Other optometrist in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →